logo
Resident in affluent Aussie suburb found living for years with dire mould problem in public housing

Resident in affluent Aussie suburb found living for years with dire mould problem in public housing

Yahoo07-07-2025
Shocking images show the "unliveable conditions" an elderly resident had been enduring for more than seven years in public housing, with black mould spreading across the walls and carpet in the home situated in one of the country's most sought-after suburbs.
The 73-year-old resident, who asked Yahoo News to remain anonymous, had been living in the Coogee home in Sydney's Eastern Suburbs since 2016 after he suffered a stroke. Within a year, the resident started to complain about the mould to his friend and carer, Grace Thomas, who then started chasing the housing authority for assistance.
After a swift initial response — with the resident being placed in temporary accommodation while the mould issue was addressed in 2018 — further complaints of the mould reappearing and growing throughout the home fell largely on deaf ears. Yahoo News understands Homes NSW received multiple reports of mould between 2019 and 2024, and while temporary repairs were made, the overall issue was not dealt with.
It was only when the resident's electricity switched off again due to "water in the walls" — and was only turned back on by authorities — that Grace doubled down on her complaints to the housing authority.
"There was mould everywhere... it grew insurmountable," Grace told Yahoo News. "He actually placed tarps on the floor and then little rugs on the top, so that he could step out without feeling the squelch underneath his feet whenever he went to get out of bed.
"He was broken, and had given up."
Images show the black mould growing in the man's carpet, bathroom, kitchen, furniture, and even on his front door. After getting nowhere with the housing authority, Grace received an independent report from a mould specialist through BlueBay Group in October last year, who confirmed "the current environment is not safe for human living".
Grace claims she was even advised to wear a mask when visiting her friend in his home.
Grace told Yahoo News authorities had provided temporary solutions for the "horrific living conditions", but a sewage leak inside the home last month was the thing that finally pushed them into action.
"The sewage really hit a mark for me, because it was a literal biohazard... The stench of it, I nearly threw up," she said. A hygienist report was completed, and the resident was finally moved to temporary accommodation by Homes NSW, where he remains today.
Yahoo News reached out to Home NSW about the living conditions the elderly man had been living in.
"We recognise that the condition of this tenant's property has not met acceptable standards and have been working to address their concerns," a spokesperson said.
"We have been working with the tenant and several works have been completed over time to rectify mould and other maintenance issues. Some of our efforts have been delayed due to difficulties accessing the unit," they said.
In response, Grace acknowledged her elderly friend can let his "pride" get in the way of accepting help, but argued it did not excuse the lack of action from authorities over the years.
Homes NSW is now working on relocating the resident to "a more suitable, ground-floor property in the local area" and confirmed he will remain in temporary accommodation until his new unit is completed this week. Other units in the Coogee building complex are being inspected to ensure no other tenants are being affected, authorities added.
"Homes NSW is committed to providing safe, well-maintained homes that meet tenants' needs," the spokesperson said.
Tenant and housing advocate Jordan van den Berg told Yahoo News he has seen a decline in public housing reinvestment and is urging state governments to do more of it. He has expressed concerns that a lack of investment not only worsens living conditions for residents, but also exacerbates negative perceptions held by some in the community towards those who rely on public housing.
"We used to have a system where public housing rents could only be spent by the government on repairing public housing and maintaining public housing... now it's not being reinvested and it should," he said.
"This incident is definitely shocking, and it's such a shame that this gentleman has been living in these conditions... we need to fight for public housing that is good quality, accessible to anyone who wants to live in it, and not just the most desperate people in our society."
⛈️ Aussies warned over widespread danger emerging in homes after relentless weather
🌊 Tenant blasts property manager's response after daughter's room floods
😷 Disturbing photos reveal huge problem for Aussie renters
After sharing the ordeal online, Grace has been inundated with offers from fellow Sydneysiders who are willing to provide furniture for her friend's new home. She is relieved, but is concerned many others are suffering silently in public housing.
"I just don't understand how to fix this, and how people that are vulnerable or are unable to navigate these systems themselves are getting any help," she said.
"They [the authorities] only come out of the woodwork when things like this happen, where it becomes a media issue. I'm hoping they will solve his [her friend's] problem, but it doesn't solve the broader issue that they need better processes," she said.
Do you have a story tip? Email: newsroomau@yahoonews.com.
You can also follow us on Facebook, Instagram, TikTok, Twitter and YouTube.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CSL slashes 15% of workforce and offshoots vaccine division
CSL slashes 15% of workforce and offshoots vaccine division

Yahoo

time7 hours ago

  • Yahoo

CSL slashes 15% of workforce and offshoots vaccine division

Australia's largest pharmaceutical company CSL will reduce its headcount by 15% and spin off its vaccine division in response to an 'unprecedented level of challenge and volatility'. CSL expects a one-off, pre-tax restructuring cost hit of $700m-$770m in the 2026 financial year. The company has conducted a series of changes across its research & development (R&D) department, operating model, and plasma network. For example, the company closed 22 underperforming plasma centres in August 2025. CSL did not disclose the areas of the company from where the 15% reduction in employee base would be initiated. As of 2024, CSL employs 32,000 people globally. The initiatives are expected to lead to savings of $500m-$550m progressively over the next three years, with the majority achieved by the end of the 2027 financial year. CSL said it would redirect the funds to 'high priority opportunities'. While most of CSL's revenue comes from its blood plasma treatments for rare illnesses, the pharma company is also one of the world's largest influenza vaccine manufacturers. It supplies more than 130 million doses of seasonal influenza doses globally each year in its Afluria, Fluad and Flucelvax brands. CSL also announced a planned spin-off of its vaccine division, known as CSL Seqirus. The company did not disclose a valuation for the demerger, which is slated to be completed in early 2026 and produce a publicly listed company in Australia, but CEO Dr Paul McKenzie said it would help 'reshape and simplify the [core] business'. Profit in the vaccine unit dipped due to reduced demand in the US – a revenue area the company hopes to address in 2026. "We firmly believe that a simplified and focused CSL is best for patients, best for our people, and best for our shareholders,' McKenzie added. The company said it would also buy back A$750m ($486.50m) of shares this financial year, partaking in a wider trend of share buybacks across the global pharma industry. Sanofi and Eli Lilly are both undertaking billion-dollar share buyback programmes. The significant restructuring, announced on CSL's 2025 financial year earnings report, eclipsed what was a positive year for the company. Net profit after tax was $3bn for the past 12 months up to June 2025, a rise of 15% on constant currencies. CSL's headcount reduction and vaccine spinoff dragged shares down 9.5%, from A$271.32 at market close on 18 August to A$245.45 at market open on 19 August. The Australian-listed company has a market cap of A$109.1bn, making it the country's fifth-largest company. In regard to impacts from tariffs, McKenzie said CSL's strategic initiatives would not be impacted due to its heavy US manufacturing presence. His statement echoed wider sentiment shared by big pharma company execs in the Q2 earnings window, many of whom expect minimal impact. Navigate the shifting tariff landscape with real-time data and market-leading analysis. Request a free demo for GlobalData's Strategic Intelligence . "CSL slashes 15% of workforce and offshoots vaccine division" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

US Vaccine Fatigue Will Fade, CSL CEO Says
US Vaccine Fatigue Will Fade, CSL CEO Says

Yahoo

time12 hours ago

  • Yahoo

US Vaccine Fatigue Will Fade, CSL CEO Says

CSL CEO and Managing Director Paul McKenzie says the time is right to spin off its Seqirus business as vaccine demand grows and "fatigue" fades in the US, especially among the ageing population. The Australian biotech giant's shares plunged the most in 23 years after it reported disappointing earnings. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

ASX Penny Stocks Spotlight: Berkeley Energia And 2 Other Noteworthy Picks
ASX Penny Stocks Spotlight: Berkeley Energia And 2 Other Noteworthy Picks

Yahoo

time13 hours ago

  • Yahoo

ASX Penny Stocks Spotlight: Berkeley Energia And 2 Other Noteworthy Picks

Australian shares are experiencing a downturn, with the ASX 200 futures showing a slight decline amid cautious sentiment surrounding the government's Economic Reform Roundtable and reactions to Wall Street's recent highs. In such uncertain market conditions, investors often look beyond established names to explore opportunities in smaller or newer companies. Penny stocks, despite being considered an outdated term, continue to intrigue investors with their potential for growth at lower price points. Top 10 Penny Stocks In Australia Name Share Price Market Cap Financial Health Rating Alfabs Australia (ASX:AAL) A$0.45 A$124.67M ★★★★☆☆ EZZ Life Science Holdings (ASX:EZZ) A$2.49 A$117.93M ★★★★★★ GTN (ASX:GTN) A$0.4025 A$77.22M ★★★★★★ IVE Group (ASX:IGL) A$2.965 A$461M ★★★★★☆ West African Resources (ASX:WAF) A$2.715 A$3.09B ★★★★★★ Regal Partners (ASX:RPL) A$3.10 A$1.05B ★★★★★★ Bravura Solutions (ASX:BVS) A$2.08 A$927.98M ★★★★★★ Austco Healthcare (ASX:AHC) A$0.37 A$137.06M ★★★★★★ Bisalloy Steel Group (ASX:BIS) A$4.51 A$218.27M ★★★★★★ CTI Logistics (ASX:CLX) A$1.855 A$149.41M ★★★★☆☆ Click here to see the full list of 450 stocks from our ASX Penny Stocks screener. Let's review some notable picks from our screened stocks. Berkeley Energia Simply Wall St Financial Health Rating: ★★★★★★ Overview: Berkeley Energia Limited focuses on the exploration and development of mineral properties in Spain with a market capitalization of A$245.19 million. Operations: Currently, the company does not report any revenue segments. Market Cap: A$245.19M Berkeley Energia, with a market cap of A$245.19 million, is currently pre-revenue and focuses on mineral exploration in Spain. The company has transitioned to profitability this year and maintains a debt-free status, contrasting its previous debt to equity ratio of 55.3% five years ago. Its seasoned board and management team bring significant experience, with average tenures of 13.3 and 9.8 years respectively. Despite low Return on Equity at 1.2%, Berkeley's strong asset position covers both short-term (A$80.1M) and long-term liabilities (A$1.8M), while shareholders have not faced meaningful dilution recently. Click here and access our complete financial health analysis report to understand the dynamics of Berkeley Energia. Review our historical performance report to gain insights into Berkeley Energia's track record. Core Lithium Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Core Lithium Ltd focuses on developing lithium and various metal deposits in Northern Territory and South Australia, with a market cap of A$278.59 million. Operations: The company's revenue is primarily generated from the Finniss Lithium Project, contributing A$52.28 million. Market Cap: A$278.59M Core Lithium, with a market cap of A$278.59 million, is focused on developing lithium projects in Australia and generated A$52.28 million from its Finniss Lithium Project. The company remains unprofitable and is not expected to achieve profitability in the next three years despite revenue growth forecasts of 39.2% annually. Core Lithium has a stable financial position with short-term assets (A$60.7M) exceeding both short-term (A$32.5M) and long-term liabilities (A$14.6M). The management team averages 1.3 years in tenure, suggesting recent changes, while the board has more experience with an average tenure of 8.4 years. Get an in-depth perspective on Core Lithium's performance by reading our balance sheet health report here. Understand Core Lithium's earnings outlook by examining our growth report. PolyNovo Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally with a market cap of A$832.47 million. Operations: The company generates revenue of A$115.58 million from the development, manufacturing, and commercialisation of its NovoSorb Technology. Market Cap: A$832.47M PolyNovo, with a market cap of A$832.47 million, has demonstrated significant earnings growth of 270.2% over the past year, surpassing its 5-year average and industry benchmarks. The company's recent sales report shows revenue climbing to A$118.6 million for Fiscal Year 2025, a notable increase from the previous year. Despite this growth, PolyNovo's management team is relatively inexperienced with an average tenure of 1.6 years, and it faces challenges such as negative operating cash flow and low return on equity at 7.8%. However, strong short-term assets cover both short-term and long-term liabilities effectively. Navigate through the intricacies of PolyNovo with our comprehensive balance sheet health report here. Gain insights into PolyNovo's outlook and expected performance with our report on the company's earnings estimates. Where To Now? Discover the full array of 450 ASX Penny Stocks right here. Contemplating Other Strategies? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:BKY ASX:CXO and ASX:PNV. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store